Revefenacin

Revefenacin
Names
Trade namesYupelri
Clinical data
Drug classLong-acting muscarinic antagonist (LAMA)[1]
Main usesChronic obstructive pulmonary disease (COPD)[1]
Side effectsCough, upper respiratory tract infection, headache, back pain[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: N (Not classified yet)
    Routes of
    use    		Inhalation
    Typical dose175 ucg (3 mL) OD[2]
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa619009
    Legal
    Legal status
    Chemical and physical data
    FormulaC35H43N5O4
    Molar mass597.760 g·mol−1
    3D model (JSmol)
    SMILES
    • CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
    InChI
    • InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
    • Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

    Revefenacin, sold under the brand name Yupelri, is a medication used for the long term treat of chronic obstructive pulmonary disease (COPD).[1] It is used by breathing it into the lungs.[1]

    Common side effects include cough, upper respiratory tract infection, headache, and back pain.[2] Other side effects may include allergic reactions, bronchospasm, and urinary retention.[1] It is a long-acting muscarinic antagonist (LAMA).[1]

    Revefenacin was approved for medical use in the United States in 2018.[1] It is not available in the United Kingdom or Europe as of 2021.[3] In the United States it costs about 1,100 USD per month.[4]

    Medical uses

    Dosage

    It is taken at a dose of 175 mcg (3 mL) once per day.[2]

    History

    It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[5]

    References

    1. 1 2 3 4 5 6 7 "Revefenacin Monograph for Professionals". Drugs.com. Archived from the original on 17 April 2021. Retrieved 16 October 2021.
    2. 1 2 3 4 "DailyMed - YUPELRI- revefenacin solution". dailymed.nlm.nih.gov. Archived from the original on 4 August 2020. Retrieved 17 October 2021.
    3. ↑ "Revefenacin". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 17 October 2021. Retrieved 17 October 2021.
    4. ↑ "Yupelri Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 17 October 2021.
    5. ↑ Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
    External sites:
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.